Zurich-based venture capital firm Ayun has launched a new fund targeting the fast-growing longevity sector, with strategic support from longevity company builder Maximon and a group of former senior banking executives.
The fund aims to capitalize on the intersection of health, biotech, and technology, with a focus on companies that are developing solutions to extend human healthspan and address age-related diseases. Ayun plans to provide early-stage capital and guidance to startups working on breakthroughs in areas such as cellular rejuvenation, diagnostics, and preventative care.
Among the fund’s notable backers are former Credit Suisse and Julius Baer executives, many of whom have shifted focus from traditional finance to the emerging longevity economy. Ayun’s founding team, led by entrepreneurs and investors with experience in both life sciences and venture capital, intends to bridge scientific innovation with commercial scalability.
Maximon’s involvement brings additional credibility to the initiative, having previously incubated longevity ventures in Switzerland. The collaboration is part of a broader trend where Swiss and international investors are increasingly viewing longevity not just as a health issue, but as a major economic opportunity.
Ayun is currently reviewing investment opportunities in both Europe and Silicon Valley, positioning itself as a cross-continental player in a sector projected to see significant growth over the next decade.
